Printer Friendly

Y's Therapeutics initiates Phase II trial with YSPSL to prevent ischemic reperfusion injury in liver transplant patients.

Y's Therapeutics, Tokyo, Japan and Burlingame, CA, announced it has initiated a Phase II clinical trial of its lead compound, YSPSL, for prevention of ischemic reperfusion injury (I'R) in liver transplant recipients. The trials is a randomized, double-blind, placebo-controlled study designed to enroll 12 patients undergoing cadaveric orthotopic liver transplantation at Dumont UCLA Transplant Center in Los Angeles, CA.

The availability of usable livers for transplantation is limited by the risk of I/R injury, an inflammatory reaction when blood re-flows into ischemic tissue, i.e., the newly transplanted liver. The injury may lead to poor short and long-term graft function which could threaten the survival of the transplanted liver.

The company reports YSPSL has been demonstrated in a number of animal models including transplant, chronic inflammation and myocardial reperfusion, to block the selectin/ligand interaction, thereby preventing tissue damage from inappropriate inflammation. Y's says YSPSL has been tested in several clinical studies in patients, demonstrating a clinical safety profile similar to placebo. The drug has not yet been approved for use in any indication.

Contact: John Wulf - (650) 777-7000; e-mail: bizdev@ysthera.com; Web site: www.ysthera.com
COPYRIGHT 2007 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:May 1, 2007
Words:189
Previous Article:TransMedics says trial of Organ Care System successfully perfused heart for transplantation.
Next Article:MTF, Ethicon, Inc., sign marketing agreement for FlexHD Acellular Dermal Matrix.
Topics:


Related Articles
Prevention of ischemia/reperfusion injury in liver transplants. (South Carolina Junior Academy Of Sciences Abstracts).
Y's Therapeutics initiates Phase II clinical trial to evaluate YSPSL in prevention of delayed graft function.
ANADYS INITIATES 28-DAY CLINICAL TRIAL OF ANA975.
Nabi Biopharmaceuticals granted Fast Track Designation by FDA for Civacir to prevent HCV re-infection in liver transplant patients.
ORPHAN THERAPEUTICS COMPLETES ENROLLMENT FOR TERLIPRESSIN.
FIRST HEART ATTACK PATIENT ENROLLED IN RAPID MI-ICE STUDY.
TransMedics says trial of Organ Care System successfully perfused heart for transplantation.
ViroPharma initiates Phase 3 study of maribavir in liver transplant patients.
PROGEN REPORTS ON PHASE 3 OF PI-88 FOR LIVER CANCER.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |